Research progress of N6-methyladenosine in colorectal cancer: A review.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
24 Nov 2023
24 Nov 2023
Historique:
medline:
29
11
2023
pubmed:
28
11
2023
entrez:
28
11
2023
Statut:
ppublish
Résumé
Colorectal cancer is the third most common malignant tumor worldwide, causing serious harm to human health. Epigenetic modification, especially RNA methylation modification, plays a critical role in the occurrence and development of colorectal cancer via post-transcriptional regulation of mRNA and non-coding RNA expression. Among these, N6-methyladenosine (m6A) is the most common chemical modification in mammals, which plays an important role in the progress of cancer, including colorectal cancer. m6A is a dynamic and reversible process and is mainly regulated by m6A methyltransferase ("writers"), m6A demethylases ("erasers"), and m6A binding proteins ("readers"). Herein, we reviewed recent advances in the role of m6A modification in colorectal cancer and focused on the factors affecting m6A modification. Furthermore, we discussed the clinical application of m6A modifications for colorectal cancer diagnosis, prognosis, and treatment and provided guides in clinical practice. m6A modification and m6A regulators play significant roles in the occurrence and development of colorectal cancer by regulating the stability and translation of mRNAs, the maturation of miRNAs, and the function of lncRNAs. m6A regulators can play biological roles in colorectal cancer through m6A-dependent manner or m6A-independent manner. Multiplies of internal factors, including miRNAs and lncRNAs, and external factors can also regulate the m6A modification by completing with m6A regulators in a base complement manner, regulating the expression of m6A and mutating the m6A site. m6A regulators and m6A modificantion are diagnostic and prognostic markers for CRC. Therefore, m6A regulators and m6A modificantion may be potential therapeutic target for CRC in the future.
Identifiants
pubmed: 38013272
doi: 10.1097/MD.0000000000036394
pii: 00005792-202311240-00016
pmc: PMC10681580
doi:
Substances chimiques
RNA, Long Noncoding
0
MicroRNAs
0
Adenosine
K72T3FS567
RNA, Messenger
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e36394Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
Nassar FJ, Msheik ZS, Itani MM, et al. Circulating miRNA as biomarkers for colorectal cancer diagnosis and liver metastasis. Diagnostics (Basel). 2021;11:341.
Allen J, Sears CL. Impact of the gut microbiome on the genome and epigenome of colon epithelial cells: contributions to colorectal cancer development. Genome Med. 2019;11:11.
Raskov H, Søby JH, Troelsen J, et al. Driver gene mutations and epigenetics in colorectal cancer. Ann Surg. 2020;271:75–85.
Hegazy RA, Hegazy AA, Abdel-Aziz HR, et al. Expression of β-catenin and cyclooxygenase 2 in colorectal carcinoma: an immunohistochemical study. Univers J Med Sci. 2013;1:72–7.
Boccaletto P, Machnicka MA, Purta E, et al. MODOMICS: a database of RNA modification pathways 2017 update. Nucleic Acids Res. 2018;46:D303–7.
Dominissini D, Nachtergaele S, Moshitch-Moshkovitz S, et al. The dynamic N 1 -methyladenosine methylome in eukaryotic messenger RNA. Nature. 2016;530:441–6.
Lin S, Liu Q, Lelyveld VS, et al. Mettl1/Wdr4-Mediated m 7 G tRNA methylome is required for normal mRNA translation and embryonic stem cell self-renewal and differentiation. Mol Cell. 2018;71:244–255.e5.
Shi H, Chai P, Jia R, et al. Novel insight into the regulatory roles of diverse RNA modifications: re-defining the bridge between transcription and translation. Mol Cancer. 2020;19:78.
Huber SM, van Delft P, Mendil L, et al. Formation and abundance of 5-hydroxymethylcytosine in RNA. Chembiochem. 2015;16:752–5.
Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci USA. 1974;71:3971–5.
Roundtree IA, Evans ME, Pan T, et al. Dynamic RNA modifications in gene expression regulation. Cell. 2017;169:1187–200.
Coker H, Wei G, Brockdorff N. m6A modification of non-coding RNA and the control of mammalian gene expression. Biochim Biophys Acta Gene Regul Mech. 2019;1862:310–8.
Huang H, Weng H, Chen J. m 6 A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer. Cancer Cell. 2020;37:270–88.
Meyer KD, Saletore Y, Zumbo P, et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3′UTRs and near stop codons. Cell. 2012;149:1635–46.
Rottman FM, Bokar JA, Narayan P, et al. N6-adenosine methylation in mRNA: substrate specificity and enzyme complexity. Biochimie. 1994;76:1109–14.
Wang X, Feng J, Xue Y, et al. Structural basis of N 6 -adenosine methylation by the METTL3-METTL14 complex. Nature. 2016;534:575–8.
Zhang X, Li MJ, Xia L, et al. The biological function of m6A methyltransferase KIAA1429 and its role in human disease. PeerJ. 2022;10:e14334.
Scholler E, Weichmann F, Treiber T, et al. Interactions, localization, and phosphorylation of the m 6 A generating METTL3-METTL14-WTAP complex. RNA. 2018;24:499–512.
Moindrot B, Cerase A, Coker H, et al. A Pooled shRNA screen identifies Rbm15, Spen, and Wtap as factors required for Xist RNA-Mediated silencing. Cell Rep. 2015;12:562–72.
Knuckles P, Lence T, Haussmann IU, et al. Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the m 6 A machinery component Wtap/Fl 2 d. Genes Dev. 2018;32:415–29.
Aoyama T, Yamashita S, Tomita K. Mechanistic insights into m6A modification of U6 snRNA by human METTL16. Nucleic Acids Res. 2020;48:5157–68.
Xing M, Liu Q, Mao C, et al. The 18S rRNA m 6 A methyltransferase METTL5 promotes mouse embryonic stem cell differentiation. EMBO Rep. 2020;21:e49863.
Pinto R, Vågbø CB, Jakobsson ME, et al. The human methyltransferase ZCCHC4 catalyses N6-methyladenosine modification of 28S ribosomal RNA. Nucleic Acids Res. 2020;48:830–46.
Jia G, Fu Y, Zhao X, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7:885–7.
Zheng G, Dahl JA, Niu Y, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. 2013;49:18–29.
Patil DP, Pickering BF, Jaffrey SR. Reading m 6 A in the transcriptome: m 6 A-Binding proteins. Trends Cell Biol. 2018;28:113–27.
Meyer KD, Jaffrey SR. Rethinking m 6 A readers, writers, and erasers. Annu Rev Cell Dev Biol. 2017;33:319–42.
Lin S, Choe J, Du P, et al. The m 6 A Methyltransferase METTL3 promotes translation in human cancer cells. Mol Cell. 2016;62:335–45.
He L, Li H, Wu A, et al. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18:176.
Yue Y, Liu J, Cui X, et al. VIRMA mediates preferential m 6 A mRNA methylation in 3′UTR and near stop codon and associates with alternative polyadenylation. Cell Discov. 2018;4:10.
Mauer J, Sindelar M, Despic V, et al. FTO controls reversible m 6 Am RNA methylation during snRNA biogenesis. Nat Chem Biol. 2019;15:340–7.
Wang X, Zhao BS, Roundtree IA, et al. N 6 -methyladenosine modulates messenger RNA translation efficiency. Cell. 2015;161:1388–99.
Shi H, Wang X, Lu Z, et al. YTHDF3 facilitates translation and decay of N 6 -methyladenosine-modified RNA. Cell Res. 2017;27:315–28.
Xiao W, Adhikari S, Dahal U, et al. Nuclear m 6 A reader YTHDC1 regulates mRNA splicing. Mol Cell. 2016;61:507–19.
Roundtree IA, Luo GZ, Zhang Z, et al. YTHDC1 mediates nuclear export of N 6 -methyladenosine methylated mRNAs. Elife. 2017;6:e31311.
Huang H, Weng H, Sun W, et al. Recognition of RNA N 6 -methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20:285–95.
Meyer KD, Patil DP, Zhou J, et al. 5′UTR m 6 A promotes cap-independent translation. Cell. 2015;163:999–1010.
Shen C, Xuan B, Yan T, et al. m 6 A-dependent glycolysis enhances colorectal cancer progression. Mol Cancer. 2020;19:72.
Li T, Hu PS, Zuo Z, et al. METTL3 facilitates tumor progression via an m 6 A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019;18:112.
Xiang S, Liang X, Yin S, et al. N6-methyladenosine methyltransferase METTL3 promotes colorectal cancer cell proliferation through enhancing MYC expression. Am J Transl Res. 2020;12:1789–806.
Zhu W, Si Y, Xu J, et al. Methyltransferase like 3 promotes colorectal cancer proliferation by stabilizing CCNE1 mRNA in an m6A-dependent manner. J Cell Mol Med. 2020;24:3521–33.
Deng R, Cheng Y, Ye S, et al. m 6 A methyltransferase METTL3 suppresses colorectal cancer proliferation and migration through p38/ERK pathways. Onco Targets Ther. 2019;12:4391–402.
De Filippo C, Castagnini C, Toti S, et al. IGF2BP2 promotes colorectal cancer cell proliferation and survival through interfering with RAF-1 degradation by miR-195. Cell Oncol (Dordr). 2016;590:1641–50.
Shantha Kumara H, Kirchoff D, Caballero OL, et al. Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target. Oncoscience. 2015;2:607–14.
Lochhead P, Imamura Y, Morikawa T, et al. Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer. 2012;48:3405–13.
Wei Q, Huang X, Fu B, et al. IMP3 expression in biopsy specimens of colorectal cancer predicts lymph node metastasis and TNM stage. Int J Clin Exp Pathol. 2015;8:11024–32.
Huang X, Wei Q, Liu J, et al. Analysis of IMP3 expression in primary tumor and stromal cells in patients with colorectal cancer. Oncol Lett. 2017;14:7304–10.
Wei Q, Zhou H, Zhong L, et al. IMP3 expression in biopsy specimens as a diagnostic biomarker for colorectal cancer. Hum Pathol. 2017;64:137–44.
Xu W, Sheng Y, Guo Y, et al. Increased IGF2BP3 expression promotes the aggressive phenotypes of colorectal cancer cells in vitro and vivo. J Cell Physiol. 2019;234:18466–79.
Li K, Huang F, Li Y, et al. Stabilization of oncogenic transcripts by the IGF2BP3/ELAVL1 complex promotes tumorigenicity in colorectal cancer. Am J Cancer Res. 2020;10:2480–94.
Xu J, Chen Q, Tian K, et al. m6A methyltransferase METTL3 maintains colon cancer tumorigenicity by suppressing SOCS2 to promote cell proliferation. Oncol Rep. 2020;44:973–86.
Chen X, Xu M, Xu X, et al. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer. Mol Cancer. 2020;19:106.
Zhu D, Zhou J, Zhao J, et al. ZC3H13 suppresses colorectal cancer proliferation and invasion via inactivating Ras-ERK signaling. J Cell Physiol. 2019;234:8899–907.
Vu LP, Pickering BF, Cheng Y, et al. The N 6 -methyladenosine (m 6 A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med. 2017;23:1369–76.
Chen H, Gao S, Liu W, et al. RNA m 6 A methyltransferase METTL3 facilitates colorectal cancer by activating m(6)A-GLUT1-mTORC1 axis and is a therapeutic target. Gastroenterology. 2020;160:1284–300.
Saberinia A, Alinezhad A, Jafari F, et al. Oncogenic miRNAs and target therapies in colorectal cancer. Clin Chim Acta. 2020;508:77–91.
Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010;79:351–79.
Chou CH, Shrestha S, Yang CD, et al. miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 2018;46:D296–302.
Alarcón CR, Lee H, Goodarzi H, et al. N6-methyladenosine marks primary microRNAs for processing. Nature. 2015;519:482–5.
Mirihana Arachchilage G, Dassanayake AC, Basu S. A potassium ion-dependent RNA structural switch regulates human pre-miRNA 92b maturation. Chem Biol. 2015;22:262–72.
Peng W, Li J, Chen R, et al. Upregulated METTL3 promotes metastasis of colorectal Cancer via miR-1246/SPRED2/MAPK signaling pathway. J Exp Clin Cancer Res. 2019;38:393.
Chen X, Xu M, Xu X, et al. METTL14 suppresses CRC progression via regulating N6-methyladenosine-dependent primary miR-375 processing. Mol Ther. 2020;28:599–612.
Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152:1298–307.
Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;172:393–407.
Taniue K, Kurimoto A, Takeda Y, et al. ASBEL-TCF3 complex is required for the tumorigenicity of colorectal cancer cells. Proc Natl Acad Sci USA. 2016;113:12739–44.
Wu Y, Yang X, Chen Z, et al. m 6 A-induced lncRNA RP11 triggers the dissemination of colorectal cancer cells via upregulation of Zeb1. Mol Cancer. 2019;18:87.
Chen DL, Chen LZ, Lu YX, et al. Long noncoding RNA XIST expedites metastasis and modulates epithelial-mesenchymal transition in colorectal cancer. Cell Death Dis. 2017;8:e3011.
Patil DP, Chen CK, Pickering BF, et al. m 6 A RNA methylation promotes XIST-mediated transcriptional repression. Nature. 2016;537:369–73.
Yang X, Zhang S, He C, et al. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST. Mol Cancer. 2020;19:46.
Ni W, Yao S, Zhou Y, et al. Long noncoding RNA GAS5 inhibits progression of colorectal cancer by interacting with and triggering YAP phosphorylation and degradation and is negatively regulated by the m 6 A reader YTHDF3. Mol Cancer. 2019;18:143.
Ashwal-Fluss R, Meyer M, Pamudurti NR, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;56:55–66.
Han D, Li J, Wang H, et al. Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression. Hepatology. 2017;66:1151–64.
Chen RX, Chen X, Xia LP, et al. N 6 -methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis. Nat Commun. 2019;10:4695.
Yang P, Wang Q, Liu A, et al. ALKBH5 holds prognostic values and inhibits the metastasis of colon cancer. Pathol Oncol Res. 2020;26:1615–23.
Gao T, Liu X, He B, et al. Long non-coding RNA 91H regulates IGF2 expression by interacting with IGF2BP2 and promotes tumorigenesis in colorectal cancer. Artif Cells Nanomed Biotechnol. 2020;48:664–71.
Song P, Feng L, Li J, et al. β-catenin represses miR455-3p to stimulate m6A modification of HSF1 mRNA and promote its translation in colorectal cancer. Mol Cancer. 2020;19:129.
Zheng Q, Bao C, Guo W, et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat Commun. 2016;7:11215.
Chen T, Hao YJ, Zhang Y, et al. m 6 A RNA methylation is regulated by microRNAs and promotes reprogramming to pluripotency. Cell Stem Cell. 2015;16:289–301.
Xie L, Li S, Jin J, et al. Genetic variant in miR-21 binding sites is associated with colorectal cancer risk. J Cell Mol Med. 2019;23:2012–9.
Shen XP, Ling X, Lu H, et al. Low expression of microRNA-1266 promotes colorectal cancer progression via targeting FTO. Eur Rev Med Pharmacol Sci. 2018;22:8220–6.
Yue C, Chen J, Li Z, et al. microRNA-96 promotes occurrence and progression of colorectal cancer via regulation of the AMPKα2-FTO-m6A/MYC axis. J Exp Clin Cancer Res. 2020;39:240.
Wang Y, Lu JH, Wu QN, et al. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Mol Cancer. 2019;18:174.
Jin P, Huang Y, Zhu P, et al. CircRNA circHIPK3 serves as a prognostic marker to promote glioma progression by regulating miR-654/IGF2BP3 signaling. Biochem Biophys Res Commun. 2018;503:1570–4.
Zeng K, Chen X, Xu M, et al. CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7. Cell Death Dis. 2018;9:417.
Panneerdoss S, Eedunuri VK, Yadav P, et al. Cross-talk among writers, readers, and erasers of m 6 A regulates cancer growth and progression. Sci Adv. 2018;4:eaar8263.
Tian J, Ying P, Ke J, et al. ANKLE1 N 6 -Methyladenosine-related variant is associated with colorectal cancer risk by maintaining the genomic stability. Int J Cancer. 2020;146:3281–93.
Uddin MB, Roy KR, Hosain SB, et al. An N 6 -methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells. Biochem Pharmacol. 2019;160:134–45.
Meng Y, Li S, Gu D, et al. Genetic variants in m6A modification genes are associated with colorectal cancer risk. Carcinogenesis. 2020;41:8–17.
Yamaji T, Iwasaki M, Sawada N, et al. Fat mass and obesity-associated gene polymorphisms, pre-diagnostic plasma adipokine levels and the risk of colorectal cancer: the Japan Public Health Center-based Prospective Study. PLoS One. 2020;15:e0229005.
Lambert SA, Jolma A, Campitelli LF, et al. The human transcription factors. Cell. 2018;175:598–9.
Nishizawa Y, Konno M, Asai A, et al. Oncogene c-Myc promotes epitranscriptome m 6 A reader YTHDF1 expression in colorectal cancer. Oncotarget. 2018;9:7476–86.
Guo X, Zhang Q. The emerging role of histone demethylases in renal cell carcinoma. J Kidney Cancer VHL. 2017;4:1–5.
Janney A, Powrie F, Mann EH. Host-microbiota maladaptation in colorectal cancer. Nature. 2020;585:509–17.
Wang X, Li Y, Chen W, et al. Transcriptome-wide reprogramming of N6-methyladenosine modification by the mouse microbiome. Cell Res. 2018;29:167–70.
Zhang W, Jiang KW. Role of gut microbiota in carcinogenesis and treatment for colorectal cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 2020;23:516–20.
Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr. 2003;133:2485S–93S.
Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008;15:678–85.
Wykoff CC, Pugh CW, Harris AL, et al. The HIF pathway: implications for patterns of gene expression in cancer. Novartis Found Symp. 2001;240:212–25; discussion 225.
Fry NJ, Law BA, Ilkayeva OR, et al. N 6 -methyladenosine is required for the hypoxic stabilization of specific mRNAs. RNA. 2017;23:1444–55.
Wang YJ, Yang B, Lai Q, et al. Reprogramming of m 6 A epitranscriptome is crucial for shaping of transcriptome and proteome in response to hypoxia. RNA Biol. 2020;18:131–43.
Tanabe A, Tanikawa K, Tsunetomi M, et al. RNA helicase YTHDC2 promotes cancer metastasis via the enhancement of the efficiency by which HIF-1α mRNA is translated. Cancer Lett. 2016;376:34–42.
Wang K, Feng X, Chai L, et al. The metabolism of berberine and its contribution to the pharmacological effects. Drug Metab Rev. 2017;49:139–57.
Zhang Y, Liu X, Yu M, et al. Berberine inhibits proliferation and induces G0/G1 phase arrest in colorectal cancer cells by downregulating IGF2BP3. Life Sci. 2020;260:118413.
Kupsco A, Gonzalez G, Baker BH, et al. Associations of smoking and air pollution with peripheral blood RNA N(6)-methyladenosine in the Beijing truck driver air pollution study. Environ Int. 2020;144:106021.
Zhang J, Bai R, Li M, et al. Excessive miR-25-3p maturation via N 6 -methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Nat Commun. 2019;10:1858.
Marcuello M, Vymetalkova V, Neves RPL, et al. Circulating biomarkers for early detection and clinical management of colorectal cancer. Mol Aspects Med. 2019;69:107–22.
Huang W, Qi CB, Lv SW, et al. Determination of DNA and RNA methylation in circulating tumor cells by mass spectrometry. Anal Chem. 2016;88:1378–84.
Liu X, Liu L, Dong Z, et al. Expression patterns and prognostic value of m 6 A-related genes in colorectal cancer. Am J Transl Res. 2019;11:3972–91.
Bai Y, Yang C, Wu R, et al. YTHDF1 regulates tumorigenicity and cancer stem cell-like activity in human colorectal carcinoma. Front Oncol. 2019;9:332.
Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012;10:717–28.
Zhang Y, Kang M, Zhang B, et al. m 6 A modification-mediated CBX8 induction regulates stemness and chemosensitivity of colon cancer via upregulation of LGR5. Mol Cancer. 2019;18:185.
Secretariat MA. KRAS testing for Anti-EGFR therapy in advanced colorectal cancer: an evidence-based and economic analysis. Ont Health Technol Assess Ser. 2010;10:1–49.
Mackedenski S, Wang C, Li WM, et al. Characterizing the interaction between insulin-like growth factor 2 mRNA-binding protein 1 (IMP1) and KRAS expression. Biochem J. 2018;475:2749–67.
Han D, Liu J, Chen C, et al. Anti-tumour immunity controlled through mRNA m 6 A methylation and YTHDF1 in dendritic cells. Nature. 2019;566:270–4.
Wang L, Hui H, Agrawal K, et al. m 6 A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. EMBO J. 2020;39:e104514.
Tsuruta N, Tsuchihashi K, Ohmura H, et al. RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells. Biochem Biophys Res Commun. 2020;530:235–9.
Lim SH, Zhang Y, Zhang J. Cancer-testis antigens: the current status on antigen regulation and potential clinical use. Am J Blood Res. 2012;2:29–35.
Ma L, Lin Y, Sun SW, et al. KIAA1429 is a potential prognostic marker in colorectal cancer by promoting the proliferation via downregulating WEE1 expression in an m6A-independent manner. Oncogene. 2022;41:692–703.